



31 July 2012  
Company Announcements Office  
Australian Stock Exchange  
Level 6, 20 Bridge Street  
Sydney NSW 2000

**Appendix 4C for the quarter ending 30 June 2012 (ASX:ADO)** Anteo Diagnostics Limited (ASX : ADO) attaches its Appendix 4C for the quarter ending 30 June 2012.

### **CEO REPORT - QUARTER ENDED 30 June 2012**

Dear Shareholders,

Anteo Diagnostics Limited (ASX:ADO) is pleased to report on its activities for the quarter ending 30 June 2012. This quarter had the following highlights:

- Liaising with eBioscience with to ensure rapid uptake of the use of Mix&Go
- Allowance of Generation of Surface Coating Diversity patent in the US
- Filing of divisional application for Use of Metal Complexes patent in US
- Presentations on our technology and the investment opportunity offered by our company in a range of domestic and international forums
- Addressed “non specific binding” identified in immunoprecipitation studies with major collaborator
- Development of a universal protein conjugation kit for use on nanospheres (beads)
- Progressed studies on Point of Care applications for Mix&Go

#### **eBIOSCIENCE**

Anteo is working closely with eBioscience to assist with and facilitate the rapid migration of all relevant tests to include the use of Mix&Go. In the first instance this will be bead based immunoassays for use on flow cytometers. Work has also commenced on plate based applications and technical discussions on a range of novel applications have been held.

On 25<sup>th</sup> June eBioscience was acquired by Affymetrix, Inc a company that develops, manufactures and sells products and services for genetic analysis to the life science research and clinical healthcare markets. Included in the Affymetrix product range are many assays for which Mix&Go is likely to demonstrate benefit. Discussions surrounding these issues are currently in train. In consequence it is expected that the Affymerix acquisition of eBioscience will provide revenue opportunities beyond

***Anteo Diagnostics Limited*** ABN 78 090 487 273  
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@anteodx.com](mailto:contact@anteodx.com) **Web** [www.anteodx.com](http://www.anteodx.com)



those originally anticipated by Anteo. We expect these revenues opportunities to become increasingly apparent through the course of the current financial year.

## **PATENT PORTFOLIO**

The company has received a Notice of Allowance for its Generation of Surface Coating Diversity patent from the United States Patent and Trademark Office (USPTO). This patent covers the intellectual property that led to the discovery of Mix&Go. Its granting will ensure that the process used to identify Mix&Go cannot be copied in the US market and will provide Anteo with the freedom to use the same approach for the identification of new “glues” in a broad range of other sectors and industries.

Under normal circumstances the USPTO would be expected to grant the “Generation of Surface Coating Diversity” patent within three months of issuance of the Notice of Allowance.

A divisional application on the “Use of Metal Complexes” has been filed with the USPTO. The US specification of the divisional application has not been published yet and, as a result, the USPTO database does not currently show a record of this filing.

## **COMPANY PRESENTATIONS**

Over the period since my last report presentations have been delivered at a range of conferences:

- In May at the AusMedtech Annual Conference in Sydney
- In June at the Australian Life Sciences Investment Showcase in New York and
- In June at the Bio International Conference in Boston. In addition, at this meeting, we were associated with the “Australian Pavillion” and had the opportunity to progress existing collaborations with a number of companies and introduce our technology to many new, interested, parties.
- In July at the AACC Annual Meeting and Clinical Lab Expo in Los Angeles, where we expanded our presence and had a booth manned by 5 staff.

## **”NON\_SPECIFIC BINDING” IN IMMUNOPRECIPITATION**

Immunoprecipitation is a technique that is used to separate a particular protein from a mixture of proteins. We are working with one of the market leading companies in this segment to develop an improved product. Early studies indicated that, if we could eliminate non-specific binding, results using our prototype products would be greatly enhanced. As was mentioned in our last quarterly report our scientists have been working on finding solutions to this problem.

We have developed a range of non-protein “blockers” specifically designed to bind to (block) any unreacted Mix&Go sites making them unavailable to bind any unwanted material. In addition, we

***Anteo Diagnostics Limited*** ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email [contact@anteodx.com](mailto:contact@anteodx.com) Web [www.anteodx.com](http://www.anteodx.com)



have developed methods to prevent binding of unwanted material to the underlying surface – often a magnetic bead. Using a combination of these two approaches we believe we have now greatly improved our prototype immunoprecipitation product.

## **DEVELOPMENT OF A “UNIVERSAL” PROTEIN CONJUGATION KIT**

The work we undertook over the past few years with some of the major *in vitro* diagnostic (IVD) companies has highlighted the concerns amongst assay developers for non-specific binding. As mentioned above we have developed solutions to this industry wide issue, some of which are specific to Mix&Go and others are more general.

This work has also led to many refinements to our coupling approach, all developed with the intention of improving outcomes when using Mix&Go. These new “blockers”, “quenchers” and enhanced protocols are now being assessed by interested global IVD companies. An outcome of this work is that we can now offer a “universal” protein conjugation kit for companies to more quickly determine the benefits of Mix&Go. It is our belief that these assessments can occur with considerably less involvement from us than has been necessary to date. We believe this kit will be of widespread interest to the Life Science sector.

## **POINT OF CARE APPLICATIONS FOR MIX&GO AND ITS USE ON OTHER SURFACES**

Anteo scientists have undertaken a great deal of work to develop improvements in Point of Care (POC) testing that incorporate Mix&Go. Traditionally, POC testing has involved the lateral flow of solutions along membranes – often nitrocellulose. As a consequence of our recent work we believe Mix&Go can positively influence outcomes in this environment. An outcome from this work on POC applications is that several major players now share this belief and are engaging with us to further examine whether Mix&Go might assist them to overcome their specific technical issues.

There are numerous “next generation” POC devices that are currently in development many of them involving biosensors. We are working closely with a number of these companies and generating what appears to be very exciting data. These projects are long term and it is likely to be some time before the final testing, registration and sale of these devices necessary for us to achieve significant revenues will be complete. More modest revenues from Research and Collaboration Agreements and Technology Access Fees are, however, possible.

As has previously been mentioned there is a body of work being undertaken on microtitre plates. This work demonstrates the ability of Mix&Go to convert a low cost plate into one that performs as well as premium quality (and cost) plates. This data is of great attraction to many of the parties with whom we have made contact at Oak Ridge, Bio and AACC.

***Anteo Diagnostics Limited*** ABN 78 090 487 273  
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@anteodx.com](mailto:contact@anteodx.com) **Web** [www.anteodx.com](http://www.anteodx.com)



## **CORPORATE**

Anteo's cash balance at the end of June was \$4,883,176. For the year to June we were pleased to expand operational capability and yet maintain a cost regime within Board approved parameters. Given our future expenditure estimates this sum is believed to be sufficient to meet our needs through to the end of March 2014 in the absence of additional revenues. The activities outlined above enhance our expectations of revenues before that time.

We continue to be pleased with the progress Anteo is making and heartened by the progress we are making in market segments that are relatively new to us. We remain frustrated by the time it takes to reach definitive agreements but remain optimistic about likely outcomes.

**Dr Geoff Cumming**  
**CEO**  
**Anteo Diagnostics Limited**

***Anteo Diagnostics Limited*** ABN 78 090 487 273  
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@anteodx.com](mailto:contact@anteodx.com) **Web** [www.anteodx.com](http://www.anteodx.com)

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Name of entity

Anteo Diagnostics Limited

ACN or ARBN

75-070-028-625

Quarter ended  
("current quarter")

30-Jun-12

### Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (12 months) \$A'000
1.1	Receipts from customers and government grants	149	1,208
1.2	Payments for		
	(a) staff costs	(477)	(1,660)
	(b) advertising and marketing	(105)	(371)
	(c) research and development (excluding staff costs relating to R&D)	(119)	(462)
	(d) leased assets	-	-
	(e) other working capital	(213)	(1,043)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	62	401
1.5	Interest and other costs of finance paid	-	(2)
1.6	Income taxes paid	-	-
<b>Net operating cash flows</b>		<b>(703)</b>	<b>(1,929)</b>

NOTES:

--



**Payments to directors of the entity and associates of the directors**  
**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	<b>219</b>
1.25	Aggregate amount of loans to the parties included in item 1.11	<b>NIL</b>

1.26 Explanation necessary for an understanding of the transactions

--

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

<b>NIL</b>
------------

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

<b>NIL</b>
------------

**Financing facilities available**

*Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).*

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	<b>NIL</b>	<b>NIL</b>
3.2	Credit standby arrangements	<b>NIL</b>	<b>NIL</b>

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	4,759	5,492
4.2	Deposits at call	125	128
4.3	Bank overdraft		-
4.4	Other - Funds held in trust re. Open Prospectus Offer		-
<b>Total: cash at end of quarter (item 1.23)</b>		<b>4,883</b>	<b>5,620</b>

## Acquisitions and disposals of business entities

		Acquisitions <i>(Item 1.9(a))</i>	Disposals <i>(Item 1.10(a))</i>
5.1	Acquisition/disposal of subsidiary		
5.2	Place of incorporation or registration		
5.3	Consideration for acquisition or disposal		
5.4	Total net assets at date of acquisition/disposal		
5.5	Nature of business		

## Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act 2001 (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement **does** give a true and fair view of the matters disclosed.

Sign here:

Date: 31 July 2012

(Director)

Print name: **Richard Martin**